BRIEF published on 04/07/2026 at 07:05, 4 months 23 days ago Aelis Farma obtient une subvention de 458 000 € pour son programme de lutte contre l'obésité France 2030 Aelis Farma Récepteur CB1 Recherche Sur L'obésité Subvention De Nouvelle-Aquitaine
BRIEF published on 04/07/2026 at 07:05, 4 months 23 days ago Aelis Farma Secures €458k Grant for Obesity Program France 2030 Aelis Farma Obesity Research CB1 Receptor Nouvelle-Aquitaine Grant
PRESS RELEASE published on 04/07/2026 at 07:00, 4 months 23 days ago Informations privilégiées / Autres communiqués Aelis Farma reçoit 458 k€ de subvention de France 2030 en Nouvelle-Aquitaine pour son programme innovant dans l'obésité et les maladies métaboliques. Soutien non dilutif pour la recherche sur les traitements des désordres métaboliques Subvention France 2030 Obésité Aelis Farma Nouvelle-Aquitaine
PRESS RELEASE published on 04/07/2026 at 07:00, 4 months 23 days ago Inside Information / Other news releases Aelis Farma receives €458k grant under France 2030 for obesity program development, reinforcing innovation potential in metabolism field Metabolic Diseases Grant France 2030 Obesity Aelis Farma
BRIEF published on 03/21/2026 at 10:10, 5 months 8 days ago Aelis Farma Advances Phase 2B Clinical Trial for Down Syndrome Treatment Clinical Trial CB1 Receptor AEF0217 Down Syndrome Adaptive Behavior
BRIEF published on 03/21/2026 at 10:10, 5 months 8 days ago Aelis Farma fait progresser son essai clinique de phase 2B pour le traitement du syndrome de Down Essai Clinique AEF0217 Syndrome De Down Récepteur CB1 Comportement Adaptatif
PRESS RELEASE published on 03/21/2026 at 10:05, 5 months 8 days ago Informations privilégiées / Autres communiqués Aelis Farma lance avec succès l'étude clinique de Phase 2B avec AEF0217 pour traiter les troubles comportementaux et cognitifs du syndrome de Down. Recrutement actif en France, Italie et Espagne Phase 2b Étude Clinique Aelis Farma AEF0217 Syndrome De Down
PRESS RELEASE published on 03/21/2026 at 10:05, 5 months 8 days ago Inside Information / Other news releases Aelis Farma initiates Phase 2B clinical trial with AEF0217 for Down syndrome cognitive impairments, recruiting in France, Italy, and Spain. A promising first-in-class CB1-SSi inhibitor treatment Phase 2b Aelis Farma AEF0217 Down Syndrome Cognitive Impairments
BRIEF published on 01/12/2026 at 07:35, 7 months 18 days ago Aelis Farma obtient un avis favorable de l'EMA pour AEF0217 dans la trisomie 21 EMA Aelis Farma Trisomie 21 AEF0217 Développement Pédiatrique
BRIEF published on 01/12/2026 at 07:35, 7 months 18 days ago Aelis Farma receives a favorable opinion from the EMA for AEF0217 in trisomy 21 EMA Aelis Farma AEF0217 Down Syndrome Pediatric Development
Published on 08/29/2026 at 05:15, 1 day 3 hours ago Norsemont Announces Restatement of Financial Statements
Published on 08/29/2026 at 03:20, 1 day 4 hours ago BEACN Announces Financial Results for the Second Quarter of 2026
Published on 08/29/2026 at 01:15, 1 day 7 hours ago Gamma Resources Announces Increase in Private Placement to $1,750,000 and Closing of First Tranche at $872,500
Published on 08/29/2026 at 01:00, 1 day 7 hours ago Lobe Sciences Ltd. Announces Upsize to Non-Brokered Private Placement
Published on 08/28/2026 at 23:00, 1 day 9 hours ago Guanajuato Silver Grants Stock Options to Officer
Published on 08/29/2026 at 04:05, 1 day 4 hours ago INTCO Medical Reports 40.6% H1 2026 Revenue Growth, Expands World's Largest Disposable Glove Capacity to 107 Billion Pieces
Published on 08/28/2026 at 20:49, 1 day 11 hours ago Publication pursuant to Article 5(1)(b) and (3) of Regulation (EU) No. 596/2014 and Article 2(2) and (3) of the Commission Delegated Regulation (EU) No. 2016/1052 - Final Announcement
Published on 08/28/2026 at 20:42, 1 day 11 hours ago Aroundtown SA: Release of a capital market information
Published on 08/28/2026 at 19:10, 1 day 13 hours ago Invitation to Professional or Qualified Investors holding Notes to submit offers for Branicks Bridge Notes and VIB Bridge Notes
Published on 08/28/2026 at 18:01, 1 day 14 hours ago CPI Europe announces unaudited results for the first half of 2026
